Table of Contents
Metal-Based Drugs
Volume 2008, Article ID 716329, 9 pages
Review Article

Proteomic Approaches in Understanding Action Mechanisms of Metal-Based Anticancer Drugs

Department of Anatomy, The University of Hong Kong, PokFuLam Road, Hong Kong SAR, China

Received 19 November 2007; Revised 20 April 2008; Accepted 17 June 2008

Academic Editor: Rafael Moreno-Sanchez

Copyright © 2008 Ying Wang and Jen-Fu Chiu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Medicinal inorganic chemistry has been stimulating largely by the success of the anticancer drug, cisplatin. Various metal complexes are currently used as therapeutic agents (e.g., Pt, Au, and Ru) in the treatment of malignant diseases, including several types of cancers. Understanding the mechanism of action of these metal-based drugs is for the design of more effective drugs. Proteomic approaches combined with other biochemical methods can provide comprehensive understanding of responses that are involved in metal-based anticancer drugs-induced cell death, including insights into cytotoxic effects of metal-based anticancer drugs, correlation of protein alterations to drug targets, and prediction of drug resistance and toxicity. This information, when coupled with clinical data, can provide rational basses for the future design and modification of present used metal-based anticancer drugs.